{"filing":{"accession_number":"0001720580-26-000060","cik":"0001720580","ticker":"ACET","company_name":"Adicet Bio, Inc.","form":"8-K","filing_date":"2026-09-28","report_date":"2026-09-28","primary_document":"acet-20260928.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1720580/000172058026000060/acet-20260928.htm"},"events":[{"id":35326,"run_id":32535,"accession_number":"0001720580-26-000060","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Adicet Bio announced positive Phase 1 clinical data for prula-cel in systemic lupus erythematosus (SLE) with or without lupus nephritis, demonstrating 54% DORIS remission and 50% complete renal response at 12 months with a favorable safety profile. The company plans to initiate pivotal study start-up activities in Q4 2026, representing a material clinical development milestone for the company's pipeline.","company_name":"Adicet Bio, Inc.","ticker":"ACET","filing_date":"2026-09-28","form":"8-K","submitted_at":null,"items":[{"id":39342,"accession_number":"0001720580-26-000060","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Adicet Bio disclosed positive Phase 1 clinical data for prula-cel in systemic lupus erythematosus (SLE) with or without lupus nephritis, including efficacy endpoints (54% DORIS remission, 50% complete renal response at 12 months) and a favorable safety profile. The company announced plans to initiate a pivotal study in Q4 2026. This is a material clinical development milestone for a clinical-stage biotech company, but does not fit the earnings_release category (no financial results) nor any other specific taxonomy type—it is a significant operational/clinical milestone that would affect investor assessment of the company's pipeline progress and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T12:17:50.788362+00:00","company_name":"","ticker":null,"filing_date":""},{"id":39343,"accession_number":"0001720580-26-000060","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Adicet announced positive Phase 1 clinical data for prula-cel in systemic lupus erythematosus (SLE) with or without lupus nephritis (LN), including efficacy endpoints (54% DORIS remission, 50% complete renal response at 12 months) and a favorable safety profile. The company plans to initiate pivotal study start-up activities in Q4 2026. This is a material clinical development milestone for a clinical-stage biotech company, but it does not fit the earnings_release category (no financial results) nor any other specific event type. It is clearly operational/strategic in nature—a significant clinical milestone that would affect investor assessment of the company's pipeline progress and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T12:17:50.788362+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39342,"accession_number":"0001720580-26-000060","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Adicet Bio disclosed positive Phase 1 clinical data for prula-cel in systemic lupus erythematosus (SLE) with or without lupus nephritis, including efficacy endpoints (54% DORIS remission, 50% complete renal response at 12 months) and a favorable safety profile. The company announced plans to initiate a pivotal study in Q4 2026. This is a material clinical development milestone for a clinical-stage biotech company, but does not fit the earnings_release category (no financial results) nor any other specific taxonomy type—it is a significant operational/clinical milestone that would affect investor assessment of the company's pipeline progress and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T12:17:50.788362+00:00","company_name":"Adicet Bio, Inc.","ticker":"ACET","filing_date":"2026-09-28"},{"id":39343,"accession_number":"0001720580-26-000060","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Adicet announced positive Phase 1 clinical data for prula-cel in systemic lupus erythematosus (SLE) with or without lupus nephritis (LN), including efficacy endpoints (54% DORIS remission, 50% complete renal response at 12 months) and a favorable safety profile. The company plans to initiate pivotal study start-up activities in Q4 2026. This is a material clinical development milestone for a clinical-stage biotech company, but it does not fit the earnings_release category (no financial results) nor any other specific event type. It is clearly operational/strategic in nature—a significant clinical milestone that would affect investor assessment of the company's pipeline progress and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T12:17:50.788362+00:00","company_name":"Adicet Bio, Inc.","ticker":"ACET","filing_date":"2026-09-28"}]}